Acute visual loss after ipilimumab treatment for metastatic melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acute visual loss after ipilimumab treatment for metastatic melanoma
Authors
Keywords
Melanoma, Ipilimumab, Immune, Side effects, Optic neuritis, Checkpoint inhibitors
Journal
Journal for ImmunoTherapy of Cancer
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-13
DOI
10.1186/s40425-016-0170-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
- (2015) Jason N. Crosson et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma
- (2015) Dimosthenis Mantopoulos et al. JAMA Ophthalmology
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Myosite orbitaire associée à un traitement par ipilimumab
- (2013) M. Lecouflet et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy
- (2013) A. Audemard et al. DERMATOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibody therapy-associated neurological disorders
- (2011) Xavier Bosch et al. Nature Reviews Neurology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
- (2011) Grazia Graziani et al. PHARMACOLOGICAL RESEARCH
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
- (2010) Katharina C. Kaehler et al. SEMINARS IN ONCOLOGY
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now